Nicotinamide Does Not Prevent Keratinocyte Cancers in Organ Recipients
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Oral nicotinamide does not reduce the risk of keratinocyte cancers in organ transplant recipients, a study suggests.
Authors present a concise overview of the diagnosis, risk factors, and treatment of basal cell carcinoma.
Methotrexate use may be associated with an increased risk of skin cancer, but more research is needed.
A systematic review of clinical practice guidelines revealed substantial variation in recommendations for follow-up after initial treatment for keratinocyte carcinoma.
Vismodegib treatment in local advanced and metastatic basal cell carcinoma is assessed.
Mohs micrographic surgery defect sizes were 17% larger among Hispanic/Latino patients.
A retrospective study evaluated the effect of 5% imiquimod prior to Mohs surgery in patients with basal cell carcinoma.